Viking Therapeutics (NASDAQ:VKTX – Get Free Report) is scheduled to be announcing its earnings results after the market closes on Wednesday, October 23rd. Analysts expect the company to announce earnings of ($0.24) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.
Viking Therapeutics (NASDAQ:VKTX – Get Free Report) last announced its quarterly earnings data on Wednesday, July 24th. The biotechnology company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.06. During the same quarter in the prior year, the company earned ($0.19) EPS. On average, analysts expect Viking Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Viking Therapeutics Price Performance
Shares of VKTX stock opened at $65.80 on Monday. The company has a market capitalization of $7.26 billion, a price-to-earnings ratio of -70.75 and a beta of 1.00. Viking Therapeutics has a one year low of $8.28 and a one year high of $99.41. The company’s fifty day moving average price is $62.64 and its 200-day moving average price is $61.95.
Wall Street Analysts Forecast Growth
Check Out Our Latest Report on VKTX
Insiders Place Their Bets
In other Viking Therapeutics news, CEO Brian Lian sold 115,859 shares of Viking Therapeutics stock in a transaction on Tuesday, July 30th. The shares were sold at an average price of $57.58, for a total value of $6,671,161.22. Following the completion of the transaction, the chief executive officer now directly owns 2,354,927 shares of the company’s stock, valued at $135,596,696.66. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. In other Viking Therapeutics news, CEO Brian Lian sold 115,859 shares of Viking Therapeutics stock in a transaction on Tuesday, July 30th. The shares were sold at an average price of $57.58, for a total value of $6,671,161.22. Following the completion of the transaction, the chief executive officer now directly owns 2,354,927 shares of the company’s stock, valued at $135,596,696.66. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director J Matthew Singleton sold 10,300 shares of the firm’s stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $69.50, for a total transaction of $715,850.00. Following the completion of the sale, the director now owns 9,500 shares of the company’s stock, valued at $660,250. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 516,671 shares of company stock valued at $33,810,813 in the last three months. Corporate insiders own 4.70% of the company’s stock.
About Viking Therapeutics
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Recommended Stories
- Five stocks we like better than Viking Therapeutics
- How to Find Undervalued Stocks
- Is Spotify Stock Poised to Soar? Options Traders Think So
- How to Start Investing in Real Estate
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- Most active stocks: Dollar volume vs share volume
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.